J&J Buyout Of Merck Stake In Europe Was In The Works “For Some Time”
This article was originally published in The Tan Sheet
Executive Summary
Retaining rights to future Rx-to-OTC switches and a substantial one-time cash infusion were the major drivers of Merck's decision to sell its 50% stake of an OTC venture in Europe to partner Johnson & Johnson